Healthcare staffing company AMN Healthcare Services (NYSE: AMN) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 13% year on year to $717.3 million. Guidance for next quarter’s revenue was better than expected at $662.5 million at the midpoint, 1.6% above analysts’ estimates. Its non-GAAP profit of $1.16 per share was significantly above analysts’ consensus estimates.

Is now the time to buy AMN? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

AMN Healthcare Services reported a quarter that surpassed Wall Street expectations on both revenue and non-GAAP profit, yet the market reacted negatively following the results. The main drivers behind the quarter were robust growth in the Nurse and Allied segment, with management crediting improved candidate acquisition and technology-enabled recruiting for a notable increase in sales volume. CEO Cary Grace emphasized that operational improvements, particularly in AI-driven recruiting and speed of placement, led to performance above industry trends. Management also noted that a favorable reserve adjustment related to past labor disruption activities contributed to reported results.

Looking forward, AMN's guidance is shaped by ongoing strength in core staffing demand and a strategic focus on technology and process improvements across business lines. Management highlighted that persistent vacancies and rising patient volumes in healthcare systems are expected to sustain demand for travel staffing, while enhancements in their WorkWise and Passport platforms are positioned to support future growth. However, executives remain cautious about international nurse staffing, citing ongoing embassy visa delays as a headwind extending into next year. CFO Brian Scott stated, “We expect a gradual improvement in gross margin as higher-margin segments recover and new technology deployments mature through 2027.”

Key insights from management’s remarks

Management attributed the quarter’s outperformance to the Nurse and Allied segment’s accelerated volume growth, offset by challenges in international staffing and technology services.

• Nurse and Allied volume surge: The Nurse and Allied segment experienced a double-digit increase in travel nurse and allied placements, attributed to higher market demand and improved recruiting speed through AI-enabled platforms. Management pointed to operational enhancements that enabled fill rates to reach their highest levels, even compared to pandemic-era peaks.
• Labor disruption reserve benefit: A significant reserve adjustment related to past labor disruption activities boosted reported gross margin and adjusted EBITDA. This non-recurring item was highlighted as a driver of margin outperformance for the quarter, though management cautioned investors to adjust for its one-time nature in future expectations.
• International nurse headwinds: The international nurse staffing business faced sequential declines due to ongoing embassy visa appointment delays. Management expects this headwind to persist into next year, which will likely constrain growth in this segment despite overall volume resilience earlier in the year.
• Technology and Workforce Solutions pressure: Language services and VMS (vendor management system) revenues remained under pressure from pricing declines and client-specific utilization trends. Although minutes increased modestly, management cited ongoing contract renewals at lower rates and a transition to a tiered service model as continuing near-term headwinds.
• Search and leadership momentum: The Physician and Leadership Solutions segment saw strength in executive and interim search, benefiting from heightened leadership turnover and transformation initiatives within healthcare organizations. Management expects process and technology improvements in this segment to drive further gains in the coming year.

Drivers of future performance

AMN’s forward guidance is anchored in ongoing demand for flexible staffing, margin stabilization efforts, and technology upgrades, though international and technology segments present continued risks.

• Core staffing demand trends: Management expects sustained travel staffing needs due to ongoing patient volume growth and persistent vacancies in healthcare systems. The company believes its broad talent pool and technology-enabled platforms position it to capture incremental demand, but acknowledges that bill rates remain flat and clinician supply is becoming more selective, which could affect pricing.
• Margin recovery initiatives: Executives are focused on stabilizing and eventually improving gross margins, particularly by expanding global interpreter capacity in the Language Services business and driving higher-margin program wins in Nurse and Allied. CFO Brian Scott noted that continued innovation in recruiting technology and process automation is expected to improve operating leverage, albeit gradually, through 2027.
• International and tech segment risks: Management highlighted embassy delays in the international nurse business and continued pricing pressure in Technology and Workforce Solutions as key headwinds. While some improvement is anticipated as new service models are implemented and visa appointments resume, the pace and timing of recovery remain uncertain, creating risk for earnings consistency in future quarters.

Catalysts in upcoming quarters

In upcoming quarters, the StockStory team will be monitoring (1) the pace of volume growth in Nurse and Allied placements and whether bill rates begin to firm, (2) progress in process and technology upgrades across the locum tenens and language services businesses, and (3) updates on embassy visa appointment trends affecting the international nurse segment. Adoption and impact of new features in the WorkWise and Passport platforms will also be key signposts for future performance.

AMN Healthcare Services currently trades at $45.75, down from $47.42 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

Our favorite stocks right now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.